Methylphenidate: 6 agencies, 2005–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 20.4 years separate the first record, 9 Apr 2005 at SMC (Scotland), from the most recent, 29 Sep 2025 at TLV (Sweden).
TLV (Sweden) changed its position: not recommended on 14 Nov 2024, recommended by 29 Sep 2025, after a resubmission.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 4 of 23 records date from 2023 or later.
2 of these 23 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess methylphenidate, on 9 Apr 2005; TLV (Sweden) did not open a file until 14 Nov 2024 — an unusually long tail of 19.6 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 15 years in total.
4 of the 6 agencies here assessed methylphenidate more than once, HAS (France) most often at 13 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for methylphenidate.
The full ledger for methylphenidate reads 14 recommended, 4 not recommended, 3 other and 1 not assessed, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 29 Sep 2025 | Tuzulby, depottuggtablett ingår i högkostnadsskyddet | general subsidy | source |
| PBAC (Australia) | 2022 | Attention deficit hyperactivity disorder | Recommended | source |
| PHARMAC (New Zealand) | 11 Feb 2016 | Traumatic brain injury and acquired brain injury | PTAC advice: Decline · decision reached | source |
| AWMSG (Wales) | 19 Dec 2014 | ttention-Deficit/Hyperactivity Disorder (ADHD) Methylphenidate prolonged-release tablets is indicated as part of a compr… | outside AWMSG criteria | source |
| HAS (France) | 3 Oct 2012 | Listing (Transparency Committee) | ASMR V | source |
18 further decisions for methylphenidate, across 5 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- guanfacine — divergent outcome (recommended vs not recommended) on a shared indication
- idebenone — same ATC class N06B — Psychoanaleptics
- solriamfetol — same ATC class N06B — Psychoanaleptics
- piracetam — same ATC class N06B — Psychoanaleptics
- lisdexamfetamine — same ATC class N06B — Psychoanaleptics
- modafinil — same ATC class N06B — Psychoanaleptics
Coverage: 23 decisions for methylphenidate from 6 agencies, 2005 to 2025. Data to 7 Sep 2026. ATC class N06B — Psychoanaleptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.